John Simon
OvaScience has drafted General Catalyst MD John Simon onto its board of directors following the completion of a $37m (€26.6) finance deal between the two firms.
Under the new partnership, General Catalyst led the financing for a program which will see the development and commercialisation of OvaScience’s new fertility treatments based on its egg precursor cell discoveries.
Simon said: “OvaScience is rapidly advancing its patented fertility technology aimed at improving fertility outcomes, and we’re pleased to be part of a company that has a unique and differentiated approach in an area with a clear, unmet need.”